What BioAge's Upsized IPO Tells Us About The Obesity Trend
By Yeji Jesse Lee · October 1, 2024, 3:42 PM EDT
In recent days, obesity drug developer BioAge became the latest biotech to test the public waters. The firm's $198 million upsized offering signals a continued interest in the obesity market as...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login